Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)

Italian Journal of Pediatrics

Volumn 41, Issue 1, 2015, Pages

  Bollani, Lina ^a   Baraldi, Eugenio ^b   Chirico, Gaetano ^c   Dotta, Andrea ^d   Lanari, Marcello ^e   Del Vecchio, Antonello ^f   Manzoni, Paolo ^g   Boldrini, Antonio ^h   Paolillo, Piermichele ⁱ   Di Fabio, Sandra ^j   Orfeo, Luigi ^k   Stronati, Mauro ^a   Romagnoli, Costantino ^l,m  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b AO Padova   (Italy)

^c SPEDALI CIVILI   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e ASL di Imola   (Italy)

^f DI VENERE HOSPITAL   (Italy)

^g SANT ANNA HOSPITAL   (Italy)

^h UNIVERSITY OF PISA   (Italy)

ⁱ Divisione di Neonatologia   (Italy)

^j SAN SALVATORE HOSPITAL   (Italy)

^k G RUMMO HOSPITAL   (Italy)

^l FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; VIRUS DNA;

ACCUMULATION DISORDER; BRONCHIOLITIS; CLINICAL FEATURE; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DOWN SYNDROME; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG USE; ENVIRONMENTAL FACTOR; ENVIRONMENTAL SANITATION; EPIDEMIC; ESOPHAGUS ATRESIA; HEALTH EDUCATION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE DEFICIENCY; INFECTION PREVENTION; LUNG DYSPLASIA; LUNG MALFORMATION; LUNG TRANSPLANTATION; METABOLIC DISORDER; MORTALITY; MULTICENTER STUDY (TOPIC); NEUROMUSCULAR DISEASE; NONHUMAN; PRACTICE GUIDELINE; PREMATURITY; PROGNOSIS; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK FACTOR; SEASONAL VARIATION; VIRUS ISOLATION; INFANT, PREMATURE, DISEASES; ISOLATION AND PURIFICATION; NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ANTIVIRAL AGENTS; DNA, VIRAL; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84952870921     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/s13052-015-0203-x     Document Type: Review

References (73)

1. Anderson LJ, Barney S. Graham Editors Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Berlin Heidelberg: Springer-Verlag; 2013.
2. Collins PL, Melero J. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus rev. 2011;62:80-99.
3. Mastrangelo P, Hegele RG. Host and viral factors in respiratory syncytial virus infection. Curr Pediatr Rep. 2013;1:149-57.
4. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588-98.
5. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545-55.
6. Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UD, et al. Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the "Osservatorio VRS" Study (2000-2004). New Microbiol. 2006;9:35-43.
7. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134:e1474-502.
8. Zorc JJ, Hall CB. Brochiolitis: Recent evidence on diagnosis and management. Pediatrics. 2010;125:342-9.
9. Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, et al. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014;40:65. http://www.ijponline.net/content/40/1/65.
10. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013;7:CD006458. doi: 10.1002/14651858.CD006458.
11. Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Cooper CL, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax. 2014;69:1105-12.
12. Florin TA, Shaw KN, Kittick M, Yakscoe S, Zorc JJ. Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr. 2014;168:664-70.
13. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2013;7:CD006458.
14. American Academy of Pediatrics Committee on Infectious Diseases, Bronchiolitis Guidelines Committee. Technical report: updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:e620-38.
15. American Academy of Pediatrics, Committee on Infectious Diseases and bronchiolitis Guidelines Committee. Policy statement: updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415-20.
16. Macartney KK, Gorelick MH, Manning ML, Hodinka RL, Bell LM. Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. Pediatrics. 2000;106:520-6.
17. Lanari M, Prinelli F, Adorni F, Di Santo S, Faldella G, Silvestri M, et al. Maternal milk protects infants against bronchiolitis during the first year of life. Results from an Italian cohort of newborns. Early Hum Dev. 2013;89:S51-7.
18. Jones LL, Hashim A, McKeever T, Cook DG, Britton J, Leonardi-Bee J. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res. 2011;12:5. doi: 10.1186/1465-9921/12/5.
19. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65:1045-52.
20. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halinen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541-5.
21. Backman K, Piippo-Savolainen E, Ollikainen H, Koskela H, Korppi M. Increased asthma risk and impaired quality of life after bronchiolitis or pneumonia in infancy. Pediatr Pulmonol. 2014;49:318-25.
22. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Neonatal Network Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368:1791-9.
23. Jefferson T. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2011;7:CD006207.
24. MedImmune. Synagis. Palivizumab. Package Insert. Gaithersburg: MedImmune; 2012.
25. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-7.
26. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population Pharmacokinetics of Palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927-36.
27. Saez-Llorens X. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707-12.
28. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, et al. Safety, tolerance and pharmakinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:110-5.
29. La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther. 2013;26:666-71.
30. American Academy of Pediatrics. Committee on Infectious Diseases and Committee of Fetus and Newborn from Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-6.
31. American Academy of Pediatrics Committee on Infectious Diseases from the Academy of Pediatrics. Policy statement Modified Recommendations for use of Palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1694-701.
32. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, et al. Respiratory syncytial virus associated hospitalization among children less than 24 months of age. Pediatrics. 2013;132:341-8.
33. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McCannochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154:55-61.
34. Boyce TC, Mellen BG, Metchel Jr EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:856-70.
35. Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic VV, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602.
36. Lanari M, Prinelli F, Adorni F, Di Santo S, Vandini S, Silvestri M, et al. And the Study Group of Italian Society of Neonatology on Risk Factors for RSV Hospitalization. Ital J Pediatr. 2015;41:40. doi: 10.1186/s13052-015-0149-z.
37. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case-control study on the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23:815-20.
38. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial virus lower respiratory tract infection. J Pediatr. 1995;126:212-9.
39. Ambrose CS. Severe RSV Disease in preterm infants born at 29 to 35 weeks' gestation in the United States. Pediatrics. 2014;134:e1781. letter.
40. Meissner HC, Brady MT, Byngton CL, Kimberlin DW, Lieberthal AS, Maldonado YA, et al. Authors'responses in response to the letter from Ambrose. Pediatrics. 2014;134:e1782.
41. Figueras Aloy J, Carbonell Estrany X, Comité de Estándares de la SENeo. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections. An Pediatr (Barc). 2015;82:199. doi: 10.1016/j.anpedi.2014.10.004. e1-2.
42. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M, et al. European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med. 2011;24:152-7.
43. Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L, Dutch RSV Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One. 2013;8(3):e59161. doi: 10.1371/journal.pone.0059161.
44. Lanari M, Silvestri M, Rossi GA. Respiratory syncytial virus risk factors in late preterm infants. J Matern Fetal Neonatal Med. 2009;22:102-7.
45. Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Arch Dis Child. 2014;99:469-73.
46. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007;357:1946-55.
47. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-9.
48. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307:397-400.
49. Sociaty CP. Use of Palivizumab in children with congenital heart disease. Paediatr Child Health. 2003;8:631-3.
50. Kristensen K, Stensballe LG, Bjerre J, Roth D, Fisker N, Komgstad T, et al. Risk factors for respiratorysyncytial virus hospitalization in children with heart disease. Arc Dis Child. 2009;94:785-9
51. Resch B, Resch E, Müller W. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour. Paediatr Respir Rev. 2013;14:130-6.
52. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009;94:99-103.
53. Welliver Sr RC, Checcia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin. 2010;26:2175-81.
54. Resch B, Michel-Behnke I. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab. Curr Opin Cardiol. 2013;28:85-91.
55. Szabo SM, Gooch KL, Bibby MM, Vo PG, Mitchell I, Bradt P, et al. The risk of mortality among young children hospitslized for severe respiratory syncytial virus infection. Paediatr Resir Rev. 2013;13(2):S1-8.
56. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top Jr FH, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in congenital heart disease. J Pediatr. 2003;143:532-40.
57. Simon A, Prusseit J, Muller A. Respiratory Syncytial Virus Infection in Children with Neuromuscular Impairment. The Open Microbiology Journal. 2011;5(Suppl 2-M5):155-8.
58. Masumoto K, Nagata K, Uesugi T, Yamada T, Kinjo T, Hikino S, et al. Risk of respiratory syncytial virus in survivors with severe congenital diaphragmatic hernia. Pediatr Int. 2008;50:459-63.
59. Van den Hout L, Sluiter I, Gischer S, De Klein A, Rottier R, Ijsselstijin HI, et al. Can we improve outcome of congenital diaphragmatic hernia? Pediatr Surg Int. 2009;25:733-43.
60. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Resp Rev. 2009;10:148-53.
61. Afghani B, Ngo T. Severe respiratory syncytial virus infection in term infants with genetic or other underlying disorders. Pediatrics. 2008;121:868-9.
62. Wilkesmann A, Ammann RA, Schildgen O, Eis-Hübinger AM, Müller A, Seidenberg J, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007;26:485-91.
63. Lanari M, Vandini S, Capretti MG, Lazzarotto T, Faldella G. Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J Immunol Res. 2014;2014:850831. doi: 10.1155/2014/850831.
64. Zachariah P, Ruttenber M, Simoes EA. Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study. J Pediatr. 2012;160:827-31.
65. Van Beek D, Paes B, Bont L. Increased risk of RSV infection in children with Down's syndrome: clinical implementation of prophylaxis in the European union. Clin Dev Immunol. 2013;2013:801581. doi: 10.1155/2013/801581.
66. Yi H, Lanctot K, Bont L, Bloemers BLP, Weijerman M, Broers C, et al. Respiratory Syncytial Virus prophylaxis in Down Syndrome: a prospective cohort study. Pediatrics. 2014;133:1031-7.
67. Paes B, Mitchell I, Yi H, Li A, Lanctot KL, the Caress investigators. Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J. 2014;33:e29-33.
68. Robinson KA, Odelola OA, Saldanha IJ, Mckoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev. 2013;6:CD007743. doi: 10.1002/14651858.CD007743.pub4. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD007743.
69. Prescott WA, Hutchinson DJ. Respiratory Syncytial Virus prophylaxis in special populations: is it something worth considering in cystic fibrosis and immunosuppression? J Pediatr Pharmacol Ther. 2011;16:77-86.
70. Winterstein AG, Eworuke E, Dandan X, Schuler P. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis. Pediatr Pulmonol. 2013;48:874-84.
71. Gaboli M, de la Cruz ÒA, de Agüero MI, Moreno-Galdó A, Pérez GP, de Querol MS. Use of Palivizumab in Infants and Young Children with Severe Respiratory Disease: a Delphi Study. Pediatr Pulmonol. 2014;49(5):490-502. doi: 10.1002/ppul.22826.
72. Manzoni P, Paes B, Resch B, Mejias A, Ramilo O, Carbonell-Estrany X, et al. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev. 2012;88:S34-41.
73. Paes B, Mitchell I, Li K, Lancot KL. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr. 2012;171:833-41.